Professor of Public Health
areas of expertise
Viv Hope joined Public Health Institute in November 2016 as Professor of Public Health. Prior to that Viv was a Principal Scientist at Public Health England and also a Senior Lecturer at London School of Hygiene and Tropical Medicine. He has also held positions at Imperial College London and the University of Birmingham.
The focus of Viv’s work has been on the health harms, particularly infections, associated with drug use and sexual health. His other interests include homelessness and LGBT health.
University of Bath, Bath, United Kingdom, PhD
University of Birmingham, Birmingham, United Kingdom, MMedSci
Royal Holloway University of London, Egham, United Kingdom, BSc (Hons)
Professor Vivian Hope's Publications
Image and Performance Enhancing Drugs 2016 National Survey Results
This report details the findings of the National IPEDinfo Survey 2016. The National IPEDinfo Survey is a study exploring image and performance drug use in Wales, England and Scotland. The survey is a Public Health Wales initiative working collaboratively with the Public Health Institute at Liverpool John Moores University, NHS Scotland, Nine Zero Five and Public Health England. All partners contributed to the development and delivery of the survey. Further information about the National IPED Info Survey can be found at http://ipedinfo.co.uk.
Professor Vivian Hope's Papers
‘Slamming’ among men who have sex with men accessing general drug services, in response to Schmidt, AJ et al., 2016, Illicit drug use among gay and bisexual men in 44 cities: Findings from the European MSM Internet Survey (EMIS).
Professor Vivian Hope, Rachel Glass, Claire Tanner, Monica Desai
Int J Drug Policy, 49 :24-25, 2017.
Abstract Schmidt et al. (2016) findings suggested high levels of sexualised drug use among men who have sex with men (MSM) in a number of UK cities, namely Brighton, Manchester and London. The extent of the use of various drugs, including those associated with sexualised drug use, among MSM found in the study is likely to be overestimated due to the potentially leading nature of questions asked about drugs (“When was the last time you consumed…”) which could be perceived to be presenting drug use as normal.
The extent of and factors associated with self-reported overdose and self-reported receipt of naloxone among people who inject drugs (PWID) in England, Wales and Northern Ireland
Katelyn Cullen, Charlotte O'Halloran, Jaquelyn Njoroge, Lucy Jessop, Josie Smith, Professor Vivian Hope, Fortune Ncube
Int J Drug Policy, 46 :34-40, 2017.
Abstract BACKGROUND: Overdose is a major cause of death among PWID, and for opioid overdoses naloxone administration can reduce harm. However, globally there is limited national level data on the extent of non-fatal overdose and naloxone uptake. The first national level data on the extent of self-reported overdose and self-reported receipt of naloxone among UK PWID, providing a baseline to monitor the impact of the recent policy change regarding naloxone availability, is presented. METHODS: Data on self-reported overdose and receipt of naloxone during the preceding year for 2013-2014 from a national survey of PWID was analysed. Participants who reported injecting during the preceding year were included. RESULTS: Participants (3850) were predominantly male (75%); mean age was 36 years. The most commonly injected drugs were: heroin (91%), crack (45%) and amphetamine (29%). 15% (591) reported overdosing during the preceding year. There were no differences in the proportion reporting overdose by age or gender, but overdose was more common among those who: injected multiple drugs; recently ceased addiction treatment; injected with used needles/syringes; ever had transactional sex; had used a sexual health clinic or emergency department and lived in Wales or Northern Ireland. Among those reporting an overdose during the preceding year, a third reported two to four overdoses and 7.5% five or more overdoses; half reported receiving naloxone. Those reporting naloxone receipt in the preceding year were more likely to: live in Wales or Northern Ireland; ever received used needles/syringes; ever been imprisoned; and less likely to have injected two drug types. CONCLUSION: These data provide a baseline for monitoring the impact of the 2015 UK policy change to improve take-home naloxone access. Interventions tackling overdose should promote naloxone awareness and access, and target those who; are poly-drug injectors, have ceased treatment, share needles/syringes and whose drug use links to sexual activity.
Injection into the jugular vein among people who inject drugs in the United Kingdom: Prevalence, associated factors and harms
Professor Vivian Hope, Jenny Iverson, Katelyn Cullen, John V. Parry, Lisa Maher, Fortune Ncube
Int J Drug Policy, 46 :28-33, 2017.
Abstract BACKGROUND: While people who inject drugs (PWID) typically use peripheral veins, some inject into their central veins, including the femoral and jugular veins. Injection into the jugular vein can have serious adverse health consequences, including jugular vein thrombosis, deep neck infections, pneumothorax, endocarditis and sepsis. This study examined the prevalence of, and factors associated with, jugular vein injection among a large sample of PWID in the United Kingdom. METHOD: Unlinked anonymous surveys (2011-14) recruited PWID from agencies providing services to this population. Self-reported demographic and injection-related data were collected from consenting respondents using a brief questionnaire and dried blood spot samples were tested for exposure to HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV). Univariate and multivariable logistic regression were used to examine factors associated with jugular vein injection. RESULTS: Among 5261 PWID, one third had injected into a central vein in the previous 28 days, including 6% (n=339) who had injected into their jugular vein and 1% (n=52) who had used this site exclusively for recent injections. Factors independently associated with recent jugular vein injection in multivariable analysis included female gender, a lifetime history of imprisonment, sharing needles and syringes, poly-drug injection and injection into multiple body sites. Jugular vein injection was also associated with experiencing injection-related injuries, although no associations were identified with respect to exposure to blood borne viral infections. CONCLUSION: A significant minority of PWID inject into the jugular vein in the United Kingdom. Public health responses should investigate ways to support and promote good injection site management in order to minimise vascular damage and reduce problems with peripheral venous access. Women who inject drugs, PWID with a history of imprisonment and those people who are experiencing early signs of injection-related skin and soft tissue injuries are priority sub-populations for interventions.